Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that finasteride-loaded microspheres effectively treated androgenic alopecia in a mouse model, showing similar hair growth effects to orally-administered finasteride.

In this study, ritlecitinib was generally well tolerated in pediatric alopecia areata patients aged 6 to <12 years, with no severe or serious adverse events reported, and the drug's pharmacokinetic parameters were successfully characterized.

This article discusses the importance of optimizing treatment protocols for chemotherapy-induced alopecia and reports no new clinical results; the authors emphasize improving patient outcomes and quality of life.

This review found that hair antiretroviral concentration may be associated with several factors, including hair type and genetic factors, but not with race/ethnicity or alcohol use.

The FDA approved a new Pfizer drug for hair loss in teens.

This article discusses the potential of low-dose naltrexone as an adjuvant therapy for trichodynia in alopecias, noting its anti-inflammatory properties and need for further research.

This article examines the public health risks and benefits of pill organizers and cutters, concluding that healthcare professionals should guide their use to prevent potential medication stability and efficacy issues.

In this case study, researchers observed that gabapentin may cause alopecia, as a patient developed significant hair loss shortly after starting the medication for neuropathic pain, which reversed upon discontinuation.

This study found that combining ASA with conditioned medium from adipose tissue-derived MSCs may offer a promising approach for protecting against hippocampal injuries, suggesting potential synergistic therapeutic benefits that merit further investigation.

This study observed that spironolactone improved hidradenitis suppurativa in over 80% of female patients at 3 and 6 months, with no significant differences in response due to menstrual flares or polycystic ovarian syndrome, but mild adverse events were reported.

This review discusses the use of phosphodiesterase inhibitors for alopecia, finding promising preliminary results with topical caffeine for androgenetic alopecia and telogen effluvium, but limited success in alopecia areata.

This article discusses the importance of interpreting laboratory data and performing physical assessments to support pharmacists in clinical decision-making and patient consultations, but reports no new empirical findings.

This review highlights Ritlecitinib as a promising new oral treatment for Alopecia Areata, emphasizing its targeted action and potential efficacy, especially in adults and adolescents, though it notes the need for further real-world effectiveness and long-term safety studies.

This review discusses the controversial cardiovascular safety and efficacy of subcutaneous testosterone therapy in postmenopausal women, noting that its long-term use appears safe, but CV risk assessments remain disputed.

This study found that utilizing a clinical pharmacist in perioperative urological services reduced surgical cancellations and resident overtime while improving service efficiency and financial sustainability.

In this study, researchers aimed to evaluate the safety and tolerability of low-dose oral minoxidil in adolescents, as existing data on its use in this population are limited and there are no specific pediatric guidelines for prescribing it. Results are not reported.

This study presents two cases where intralesional methotrexate combined with ablative fractional CO2 laser treatment resulted in excellent outcomes for refractory alopecia areata.

PRP is useful for hair restoration, facial rejuvenation, and wound healing.

In this systematic review, significant improvements in clinical severity, patient-reported outcomes, and quality of life were reported for dupilumab compared to placebo in patients with moderate-to-severe atopic dermatitis, prurigo nodularis, and alopecia areata, supporting its efficacy and safety for these dermatological conditions.

This case report describes two transgender men using subdermal testosterone pellets for gender affirmation, finding they tolerated the treatment, but one returned to injections; firm conclusions on pellets' suitability require further study.

This bibliometric analysis found that research on platelet-rich plasma in dermatology and plastic surgery has increased, with hotspots in facial rejuvenation, scar, and alopecia treatment, particularly from the US and Italy.

Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.

This protocol details a method for inducing skin cancer in mice through chemical carcinogenesis, which studies cutaneous malignancies but does not report new findings.

This review discusses considerations for choosing antihypertensive agents in children, including factors like side effects and FDA approval status, and reports no new clinical results.

Low dose valproic acid treatment caused hair loss in a young patient.

This review discusses the potential of extracellular vesicles as a minimally invasive treatment for androgenetic alopecia, but emphasizes that most research is still in preclinical stages and more clinical trials are needed.

This review found that alopecia areata is driven by an inflammatory response and highlights the need for early, individualized treatment to address both hair loss and psychiatric comorbidities, although more research is needed for long-term management strategies.

In this pilot study, topical latanoprost acid was observed to increase hair count and improve hair follicle structure in women with androgenetic alopecia, with no serious adverse events, suggesting potential for further investigation to confirm its efficacy and safety.

In this randomized controlled trial, researchers found that a 2.5 mg daily dose of oral minoxidil was more effective than a 1 mg dose in improving hair growth parameters in patients with androgenetic alopecia over three months, with both doses being well tolerated.

This single-patient case study reported promising results for severe, corticosteroid-resistant alopecia areata, with treatment using exosomes derived from mesenchymal stromal cells leading to almost complete hair regrowth in 12 weeks and favorable changes in inflammatory markers, suggesting potential for further investigation.